Arrowhead Pharmaceuticals shared its financial results for the year ending September 30, 2026, and will hold a call to discuss them.

Nov 12, 2026, 4:05 PM ETResultsRead the original at SEC EDGAR

Good for ARWR

Arrowhead's REDEMPLO use is growing, with new prescriptions up 63% and broader U.S. coverage, and it is now prescribed in Germany and authorized in the UK. The larger use still needs FDA approval, but current launch growth makes the report favorable.

ARWR · Arrowhead Pharmaceuticals, Inc.

AI read · Good for ARWR

The AI's read

More patients and broader insurance access give Arrowhead more chances to build sales from its current treatment. Germany is already prescribing and reimbursing it, and the UK has authorized it. The FDA's STAR program may speed review for use in a much larger group, but that launch is only planned for 2027 and still needs approval. Current launch progress is happening now, so it is the stronger part of the report.

Get alerts for ARWR

Follow Arrowhead Pharmaceuticals, Inc. (ARWR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARWR

Free on the App Store and Google Play, or on the web.